Moderately hypofractionated radiotherapy, both isodose and dose-escalated, led to progression-free survival outcomes similar to that achieved with conventionally fractionated radiotherapy in patients ...
A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.
The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation ...
The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...
The 2 groups--those receiving ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy--had similar overall survival, which was 81% and 79%, respectively, at 10 years.
MedPage Today on MSN
Study questions use of prostate cancer hormone therapy in certain cases
Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...
Evaluation of post radiotherapy PSA as a prognostic and predictive biomarker in high risk prostate cancer: A secondary analysis of RTOG 0521. Results of AFU-GETUG-20: A randomised phase 3 trial of ...
According to data from two phase III trials presented at this year's American Society of Clinical Oncology Genitourinary Cancers Symposium, patients with high-risk prostate cancer had a significantly ...
A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage trial investigated a form of radiotherapy on patients who had stopped ...
SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...
NEW ORLEANS - Ochsner MD Anderson Cancer Center will be the first in the South to offer Biology-Guided Radiotherapy, joining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results